InvestSMART

Control Bionics Limited (ASX:CBL)

ALERT: Price-sensitive ASX Announcement for CBL
Current share price for CBL : $0.061 0.003 (5.17%)+
Announcement
Release
25 Aug 2026 9:49AM
Price at Release
$0.058
Full Release
download
Summary
Control Bionics Limited has announced that its NeuroStrip device, a wearable surface electromyography device, has been registered by the UK Medicines and Healthcare products Regulatory Agency (MHRA), allowing for its commercial supply in Great Britain. This registration marks a significant regulatory milestone, following its FDA registration in the US, and is part of the company’s strategy to expand its market reach internationally. The UK market, recognized for its robust rehabilitation and sports sectors, is a key target for this expansion. Initial pilot programs with notable institutions and experts are underway, with further trials scheduled to commence. The feedback from these programs is expected to play a crucial role in the company’s market strategy and expansion plans across Europe.
Key Points
  • NeuroStrip registered by UK MHRA for commercial supply
  • Registration supports commercial supply in England, Scotland, and Wales
  • Part of a global expansion strategy targeting major markets
  • Initial pilot programs and customer trials underway in the UK
  • Feedback from trials to inform market-entry and expansion strategies
  • UK market seen as a key opportunity due to its rehabilitation and sports sectors
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.